Olympus Winter & Ibe GmbH entered into a letter of intent to acquire 81.5% stake in Medi-Tate Ltd from Xenia Venture Capital Ltd (TASE:XENA), P&T International Group, Ido Kilemnik and others for approximately ¥ 27.2 billion on February 26, 2021. As of April 30, 2021 Olympus Winter & Ibe GmbH signed the definitive agreement to acquire 81.54% stake in Medi-Tate Ltd. from from Xenia Venture Capital Ltd (TASE:XENA), P&T International Group, Ido Kilemnik and others . The consideration of approximately ¥ 2.1 billion was investment, approximately ¥ 20.9 as purchase price and approximately ¥ 4.2 billion as earnout payments. The conditional payments are Contingent on achievement of an earn-out Medi-Tate Ltd by a certain date. The planned signing of the Share Purchase Agreement and the associated transaction documents is conditioned upon successful conclusion of certain negotiations among the parties. Additionally, the closing of the transaction is subject to customary closing conditions, including any third party and regulatory consents. The transaction is expected to sign agreement on March 31, 2021 and expected to close on April 30, 2021. As of April 30, 2021 the deal is expected to close on May 31, 2021. Olympus Winter & Ibe GmbH completed the acquisition of 81.5% stake in Medi-Tate Ltd from Xenia Venture Capital Ltd (TASE:XENA), P&T International Group, Ido Kilemnik and others for ¥ 28.4 billion on May 27, 2021. The shares were transferred from Olympus Corporation to Olympus Winter & Ibe GmbH on March 16, 2021.